[HTML][HTML] Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials
P Zhao, H Zhen, H Zhao, L Zhao, B Cao - BMC cancer, 2022 - Springer
Background Postoperative adjuvant cisplatin-based chemotherapy had been the standard
care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer …
care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer …
[HTML][HTML] Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small cell lung cancer: a meta-analysis of 1,283 patients
RL Chen, LL Sun, Y Cao, HR Chen, JX Zhou… - Frontiers in …, 2021 - frontiersin.org
Background Cisplatin-based chemotherapy was previously considered as the standard
adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung …
adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung …
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
H Cheng, XJ Li, XJ Wang, ZW Chen, RQ Wang… - Lung Cancer, 2019 - Elsevier
Objectives We performed this meta-analysis to compare adjuvant EGFR-TKIs with a placebo
or adjuvant chemotherapy among patients with resected non-small cell lung cancer …
or adjuvant chemotherapy among patients with resected non-small cell lung cancer …
Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis
Background The role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in the adjuvant treatment of non-small cell lung cancer (NSCLC) has not been well …
(TKIs) in the adjuvant treatment of non-small cell lung cancer (NSCLC) has not been well …
Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non–Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta …
J Raphael, M Vincent, G Boldt, PS Shah… - American Journal of …, 2019 - journals.lww.com
The role of adjuvant tyrosine kinase inhibitors (TKIs) in non–small cell lung cancer (NSCLC)
is not well defined. Recent randomized controlled trials showed a disease-free survival …
is not well defined. Recent randomized controlled trials showed a disease-free survival …
[HTML][HTML] Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis
Background A previous meta-analysis of our research team suggested survival advantage
from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) after surgery …
from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) after surgery …
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations: A Review
Importance The use of adjuvant chemotherapy for stage IB-IIIA resected non–small cell lung
cancer (NSCLC) has limited benefit for improving cure rates. The proportion of epidermal …
cancer (NSCLC) has limited benefit for improving cure rates. The proportion of epidermal …
Efficacy and safety of adjuvant EGFR TKI alone and in combination with chemotherapy for resected EGFR mutation-positive non-small cell lung cancer: A Bayesian …
X Cui, X Li, C Lv, S Yan, J Wang, N Wu - Critical Reviews in Oncology …, 2023 - Elsevier
Adjuvant therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI), alone or with chemotherapy, is used for early-stage non-small cell lung cancer …
(TKI), alone or with chemotherapy, is used for early-stage non-small cell lung cancer …
[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
[HTML][HTML] Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
H Zhai, W Zhong, X Yang, YL Wu - Translational lung cancer …, 2015 - ncbi.nlm.nih.gov
Abstract The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis and the meta-
analysis of individual participant data reported by non-small cell lung cancer (NSCLC) Meta …
analysis of individual participant data reported by non-small cell lung cancer (NSCLC) Meta …